New Key Statistics Module, Z-Score and F-Score
NAS:CYTO Key Ratios
| Market Cap $ M | 2.29 |
| Enterprise Value $ M | 1.68 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | -- |
| Price/Sales | 1.19 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | -- |
| EPS (TTM) $ | -25.80 |
| Beneish M-Score | 0 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | 72.60 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -1.05 |
| EV-to-EBITDA | -1.10 |
| PEG | -- |
| Shares Outstanding M | 3.23 |
| Net Margin (%) | -1,016.85 |
| Operating Margin % | -882.02 |
| Pre-tax Margin (%) | -1,080.90 |
| Quick Ratio | 1.80 |
| Current Ratio | 2.36 |
| ROA % (ttm) | -35.34 |
| ROE % (ttm) | -- |
| ROIC % (ttm) | -22.33 |
| Dividend Yield % | -- |
| Altman Z-Score | -21.62 |
CYTO Number of Guru Trades
CYTO Volume of Guru Trades
Gurus Latest Trades with NAS:CYTO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:CYTO is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Altamira Therapeutics Ltd Insider Transactions
No Available Data
News about NAS:CYTO
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers